GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19023732 | Colorectum | MSI-H | negative regulation of mRNA catabolic process | 12/1319 | 63/18723 | 1.32e-03 | 2.07e-02 | 12 |
GO:00457853 | Colorectum | MSI-H | positive regulation of cell adhesion | 48/1319 | 437/18723 | 1.47e-03 | 2.23e-02 | 48 |
GO:00975813 | Colorectum | MSI-H | lamellipodium organization | 15/1319 | 90/18723 | 1.48e-03 | 2.23e-02 | 15 |
GO:20010203 | Colorectum | MSI-H | regulation of response to DNA damage stimulus | 28/1319 | 219/18723 | 1.60e-03 | 2.39e-02 | 28 |
GO:00065752 | Colorectum | MSI-H | cellular modified amino acid metabolic process | 25/1319 | 188/18723 | 1.61e-03 | 2.39e-02 | 25 |
GO:00080643 | Colorectum | MSI-H | regulation of actin polymerization or depolymerization | 25/1319 | 188/18723 | 1.61e-03 | 2.39e-02 | 25 |
GO:00434883 | Colorectum | MSI-H | regulation of mRNA stability | 22/1319 | 158/18723 | 1.65e-03 | 2.44e-02 | 22 |
GO:00308323 | Colorectum | MSI-H | regulation of actin filament length | 25/1319 | 189/18723 | 1.73e-03 | 2.52e-02 | 25 |
GO:0032200 | Colorectum | MSI-H | telomere organization | 22/1319 | 159/18723 | 1.79e-03 | 2.59e-02 | 22 |
GO:00108103 | Colorectum | MSI-H | regulation of cell-substrate adhesion | 28/1319 | 221/18723 | 1.83e-03 | 2.63e-02 | 28 |
GO:00194393 | Colorectum | MSI-H | aromatic compound catabolic process | 50/1319 | 467/18723 | 2.04e-03 | 2.85e-02 | 50 |
GO:00062782 | Colorectum | MSI-H | RNA-dependent DNA biosynthetic process | 13/1319 | 75/18723 | 2.08e-03 | 2.86e-02 | 13 |
GO:0008652 | Colorectum | MSI-H | cellular amino acid biosynthetic process | 13/1319 | 76/18723 | 2.35e-03 | 3.12e-02 | 13 |
GO:00311002 | Colorectum | MSI-H | animal organ regeneration | 13/1319 | 76/18723 | 2.35e-03 | 3.12e-02 | 13 |
GO:00329563 | Colorectum | MSI-H | regulation of actin cytoskeleton organization | 40/1319 | 358/18723 | 2.58e-03 | 3.40e-02 | 40 |
GO:1901607 | Colorectum | MSI-H | alpha-amino acid biosynthetic process | 12/1319 | 68/18723 | 2.60e-03 | 3.41e-02 | 12 |
GO:00463941 | Colorectum | MSI-H | carboxylic acid biosynthetic process | 36/1319 | 314/18723 | 2.68e-03 | 3.48e-02 | 36 |
GO:0006260 | Colorectum | MSI-H | DNA replication | 31/1319 | 260/18723 | 2.83e-03 | 3.63e-02 | 31 |
GO:00160531 | Colorectum | MSI-H | organic acid biosynthetic process | 36/1319 | 316/18723 | 2.98e-03 | 3.78e-02 | 36 |
GO:00516043 | Colorectum | MSI-H | protein maturation | 34/1319 | 294/18723 | 3.02e-03 | 3.80e-02 | 34 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0002014 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062023 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0002015 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062033 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0120010 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120011 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120021 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa006208 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002010 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa012304 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120031 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa0062011 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002011 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa0123011 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa0002021 | Liver | HCC | Citrate cycle (TCA cycle) | 28/4020 | 30/8465 | 1.08e-07 | 1.44e-06 | 8.02e-07 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PC | SNV | Missense_Mutation | novel | c.1378N>A | p.Ala460Thr | p.A460T | P11498 | protein_coding | deleterious(0.01) | benign(0.108) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | novel | c.1726N>G | p.Ser576Ala | p.S576A | P11498 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
PC | SNV | Missense_Mutation | | c.619N>C | p.Val207Leu | p.V207L | P11498 | protein_coding | deleterious(0.01) | possibly_damaging(0.822) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | | c.584C>T | p.Ala195Val | p.A195V | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | rs119103242 | c.1748N>A | p.Arg583His | p.R583H | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1217G>A | p.Arg406His | p.R406H | P11498 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.730N>T | p.His244Tyr | p.H244Y | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1848N>A | p.Met616Ile | p.M616I | P11498 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD |
PC | SNV | Missense_Mutation | novel | c.151N>A | p.Arg51Ser | p.R51S | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A6SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | aromatase | SD |
PC | SNV | Missense_Mutation | | c.2395N>A | p.Asp799Asn | p.D799N | P11498 | protein_coding | tolerated(0.18) | probably_damaging(0.967) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |